Fluorescent in situ hybridisation (FISH) analysis with the probes surrounding the aniridia locus P AX6 found no abnormalities on either chromosome 11 (i.e. no increased risk of Wilms' tumour) (Fig. 2) . Preparation of cell lines to test for monozygosity showed the girls not to be genetically identical. The result of the last investigation only became available once the twins were one and a half years of age.
Discussion
Aniridia occurs at a frequency of approximately 1 in 80 000. About two-thirds of children with aniridia have affected parents, with the disorder being inherited as an autosomal dominant trait with variable expressivity. About a third of individuals with the sporadic form of aniridia also develop Wilms' tumour. Those with aniridia and Wilms' tumour are usually mentally retarded and often suffer from genitourinary symptoms (i.e. W AGR syndrome) ? Such patients are usually heterozygous for constitutional deletions of chromosomal band llp13. The aniridia gene is located about 700 kilobases telomeric to the Wilms' tumour predispos ing gene (WT1) (Fig. 2) . The aniridia gene is homologous to the mouse P AX6 gene. Mutations in the P AX6 gene have been identified in familial and sporadic forms of aniridia. 3 -5
The observation of discordance in supposed identical twins could be explained by four genetic mechanisms:
(1) Non-penetrance. Both the twins have the mutation, which either inactivates the expression of the P AX6 gene or disrupts the P AX6 gene product - The threshold amount of this protein below which aniridia would occur in the developing eye may be dependent on something else -for example, an environmental factor may allow one twin to escape the disease despite having the gene. As with all congenital eye diseases, careful examination of both parents is important to try to detect a mild form of the abnormality which has not presented as disease. In this case both parents' anterior segments were absolutely normal.
(2) Post-zygotic. The mutation may have occurred in the embryo after twinning such that only one of the twins has the mutation. Mutation may also have occurred before twinning in which case the twins differ in the degree of mosaicism for the mutation.
(3) Genomic imprinting. In a number of human genetic conditions, the nature of the disease depends upon whether it has been inherited from the mother or the father. The cell appears to recognise from which parent the gene has been inherited. This so called imprinting of the gene has been recognised in several inherited diseases, but in particular Beckwith-Weideman syndrome. The gene for this condition has been localised to the short arm of chromosome 11. At least nine cases of monozygotic twins, all females discordant for the Beckwith Weideman syndrome phenotype, have been described. 6 , 7 The possibility that all would be the same sex by chance is small. In all females, one X chromosome is inactivated in every cell, and this process, X-inactivation, appears to occur at about the same time as the division of the blastocyst that results in monozygotic twins. Since X-inactivation and monozygous twinning seem to occur at about the same time in embryological development, interfer ence or interaction of one with the other is possible. Little is known of the mechanism of imprinting. Genomic imprinting, monozygous twinning and X inactivation may be mechanically as well as tem porally related, and their interactions may provide important clues to the nature of the early develop ment process. s The WTl (Wilms' tumour predispos ing) gene, only 700 kilobases telomeric to P AX6, has been shown to be imprinted. In fetal brains only the maternal copy of WTl is expressed, whereas in the kidney both the maternal and paternal copies are expressed. 9 (4) Non-homozygosity. Despite good physical evidence for homozygosity, only molecular evidence for monozygosity is proof. Preparation of cell lines to test for identity, followed by aniridia mutation analysis, are essential. In our case, after a lengthy wait, tests of genetic identity showed the phenotypi-cally identical twins to be genotypically non-identical, i.e. non-homozygosity was the cause of aniridia seen in only one female twin.
If the twins had been monozygous, then genomic imprinting would have been the most likely mechan ism to account for aniridia in only one homozygous twin, with methylation of the DNA being generally regarded as the most likely mechanism underlying imprinting. Methylation studies could have been carried out to see whether a region close to or within the P AX6 gene was differentially methylated in such hypothetically identical twins. Any such evidence would strongly indicate imprinting of the aniridia gene as the underlying cause for such discordance. Since, by analogy to the mouse and from some evidence from humans, the P AX6 gene is expressed mostly in the developing central nervous system, the nose and developing eye, direct expres sion studies would not be possible. In such a case where discordance is observed only in female monozygous twins, and considering the closeness of P AX6 to WTl (and by analogy with Beckwith Weideman syndrome), it may be plausible that P AX6 may be imprinted such that one of the twins has a silenced copy of the P AX6 gene. We report the first described case of cystoid macular oedema (CMO) occurring in a patient with chronic
leukaemia. An initial resolution followed treatment with acetazolamide, previously thought useful only in ocular disease with blood-retinal barrier disruption and breaches in the retinal pigment epithelium. Complete resolution of CMO followed bone marrow transplantation, the unique relevance of which is discussed.
Case Report
A 50-year-old Caucasian man presented to his general practitioner with a 6 month history of malaise, weight loss and splenomegaly. More lately he had noticed deteriorating visual acuity in his left eye, although vision in the other eye seemed unaffected. Investigation revealed chronic myeloid leukaemia (CML) with confirmation of the BCR ABL gene rearrangement. Treatment was com menced with hydroxyurea and immediate haemato logical improvement was noted at 11 days. After a further 2 weeks he was in remission and the dose of hydroxyurea was reduced. At no time did the patient show features of diabetes. There is an area of retinal thickening just below the fovea.
LETTERS TO THE JOURNAL
Three months after diagnosis he presented to us with visual acuities of 6/5 right 6/60 left and no refractive improvement. Pupillary reflexes and anterior segment appearances were normal, and each retina contained a few small blot haemorrhages in its periphery. The right macula was normal but the left showed cystic changes at the fovea and several micro aneurysms (Fig. 1 ). There were no cotton wool spots or signs of vascular occlusion. Fundus fluor escein angiography confirmed CMO in the left eye ( Fig. 2) , and several hyperfluorescent points corre sponding to the micro aneurysms seen on ophthalmoscopy.
We treated the CMO with acetazolamide slow release 250 mg twice daily. There was rapid visual improvement and after 4 weeks acuity had improved to 6/5 right OS left. The CMO appeared less marked on fluorescein angiography, as were the other points of hyperfluorescence ( Fig. 3) . Treatment was stopped after 7 weeks and within 5 days acuity had fallen to 6/36, with no pinhole improvement. Acetazolamide was restarted with rapid improvement to 6/5 right 6/6 left, and visual symptoms were subsequently con trolled with acetazolamide 250 mg daily.
Eight months after presentation the patient under went sibling allogeneic bone marrow transplant ( BMT) from his HLA identical sister and achieved neutrophil engraftment after 27 days.
His vision was remained stable and acetazolamide was withdrawn 4 months after BMT. After a further 6 months visual acuity still measured 6/5 in each eye, with normal colour vision and retinal appearances. Fluorescein angiography at this time showed a marked decrease in hyperfluorescence both at the fovea and at the other macular locations previously exhibiting leakage (Fig. 4) .
Discussion
Fundal abnormalities are well-recognised signs of leukaemia at its presentation/ and prior to the 
